Stocks · News reference
Eli Lilly CEO Dave Ricks Engages in Public Exchange Regarding Pharmaceutical Innovation
Eli Lilly CEO Dave Ricks publicly responded to skepticism from venture investor Vinod Khosla regarding the potential for large pharmaceutical companies to drive major medical breakthroughs.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1596
Analysts Raise Price Targets for Eli Lilly Following Q3 Results
Following strong third-quarter earnings, analysts from UBS and BMO increased their price targets for Eli Lilly.
Eli Lilly 'Deserves' Stock Upside: Analyst
Eli Lilly beats Q3 estimates on Mounjaro and Zepbound growth. Analysts lift price targets as 2026 revenue guidance jumps to $92 billion.
Wells Fargo Maintains Overweight on Eli Lilly, Raises Price Target to $1500
RBC Capital Maintains Outperform on Eli Lilly, Raises Price Target to $1600